Bristol-Myers Squibb and Tsinghua University of Beijing, China, have entered a multi-year strategic partnership under which BMS will fund research efforts at Tsinghua’s School of Life Sciences to identify and validate targets in oncology and immunoscience. The collaboration will also focus on structural biology research that could serve as the basis for future drug discovery projects.
 
“This is Bristol-Myers Squibb’s first discovery collaboration in China and is an example of the company’s deepening commitment to the country,” said Francis Cuss, M.D., senior vice president, research, at BMS. “We are delighted to be working with Tsinghua University, a world-renowned and highly esteemed research-based academic institution with expertise in target identification and structural biology that will support the discovery of new medicines to fight serious diseases in China and around the world.”
 
“On April 22, 1911, almost 101 years ago, Tsinghua University was founded. We have committed ourselves to working with the finest institutions and enterprises to jointly conduct cutting-edge research. In that spirit, Tsinghua University’s School of Life Sciences is building a strategic partnership with Bristol-Myers Squibb,” said Professor Kejun Kang, vice president of Tsinghua University. “I strongly believe that future cooperation between Tsinghua University and Bristol-Myers Squibb will bring about further-reaching consequences to both organizations and I wish every success in this cooperation.”